Alcohol Withdrawal Syndrome

Overlooked and Mismanaged?

Mary G. McKinley, RN, MSN, CCRN

Patients are admitted to critical care with a myriad of problems. A problem easily overlooked is alcohol dependency and the potential development of alcohol withdrawal syndrome (AWS). Fourteen million persons in the United States abuse alcohol or are alcohol dependent. Nearly 27% of persons in the United States between the ages of 18 and 64 years meet the diagnostic criteria for alcohol dependency, making it the most prevalent addictive disease in this country. According to estimates, 1 of every 5 patients admitted to a hospital is an alcohol abuser.

When patients are admitted for problems such as trauma, alcohol is often associated as a factor, and trauma patients are more likely than other patients to be assessed for AWS. Admissions to a critical care unit because of nontrauma conditions, however, are not always so clearly linked to alcohol abuse, and AWS can easily be overlooked. Overlooking AWS can have devastating consequences and complications. Persons who abuse alcohol have mortality and morbidity rates 2 to 4 times greater than those of the general population.

The toxic effects of alcohol abuse on organs and tissues put these patients at increased risk for multiple system dysfunction. Early detection of and intervention for AWS can prevent, or at least minimize, the complications and consequences of the syndrome.

Terminology

Because confusion can exist about the different terms associated with AWS, clarification is necessary (see Sidebar). Alcohol abuse cannot be diagnosed on the basis of a set amount or frequency of alcohol consumption. Signs and symptoms of withdrawal rarely occur in persons who drink only occasionally. AWS usually occurs in persons who have been heavy drinkers for weeks or months who suddenly stop drinking. An example is a patient admitted to a critical care unit for treatment of an acute hypertensive episode who is a heavy drinker but because of the admission cannot continue the alcohol intake. An understanding of the signs and symptoms and behavioral indicators is key in recognizing patients who are at risk for AWS.
One of the main neurotransmitters in the brain affected by alcohol is the inhibitory neurotransmitter γ-aminobutyrate A (GABAA). GABAA allows more chloride to enter the neuron, making the neuronal cell membranes less likely to depolarize, thereby inhibiting the cell. A second neurotransmitter of importance in alcohol abuse is the excitatory neurotransmitter N-methyl-D-aspartate (NMDA). NMDA regulates neuron excitability, increasing depolarization of the neuronal membrane by regulating the flow of calcium into the neuron. Initially, in short-term use (1 or 2 drinks occasionally), alcohol enhances the GABAA receptors and inhibits the NMDA receptors.

The result of short-term alcohol use therefore is depression of the behavioral inhibitory centers in the cerebral cortex and the reticular activating system, causing initial euphoria, exaggerated feelings of well-being, and reduced self-control and then sedation and anesthesia (Figure 1).

The pathophysiological effects of long-term use of alcohol involve the same neurotransmitters but are complicated by tolerance and physical dependence as contributing factors to the problem of withdrawal of alcohol. Long-term alcohol intake (see Sidebar for indicators of alcohol dependence) results in a decrease in GABAA inhibitory function and an increase in NMDA excitatory function. Continued intake of alcohol causes adaptation of the central nervous system, reducing the initial, short-term effects. Abrupt cessation of intake of alcohol or withdrawal produces a rebound stimulatory effect, resulting in adrenergic hypersensitivity of the limbic system and brain stem, which can lead to irritability (manifested as aggressive behavior), tremors, and seizures.

Pathophysiology

The complex mechanisms of alcohol intoxication, tolerance, dependence, and withdrawal are not completely understood, but a clear relationship exists between alcohol and alterations in neurotransmission in the brain. Neurotransmitters are chemical messengers that transmit information from one neuron to another across synapses. Neurotransmitters in the brain either promote (excitatory) or slow down (inhibitory) impulses along the neurons.

One of the main neurotransmitters in the brain affected by alcohol is the inhibitory neurotransmitter γ-aminobutyrate A (GABAA). GABAA allows more chloride to enter the neuron, making the neuronal cell membranes less likely to depolarize, thereby inhibiting the cell. A second neurotransmitter of importance in alcohol abuse is the excitatory neurotransmitter N-methyl-D-aspartate (NMDA). NMDA regulates neuron excitability, increasing depolarization of the neuronal membrane by regulating the flow of calcium into the neuron. Initially, in short-term use (1 or 2 drinks occasionally), alcohol enhances the GABAA receptors and inhibits the NMDA receptors.

The result of short-term alcohol use therefore is depression of the behavioral inhibitory centers in the cerebral cortex and the reticular activating system, causing initial euphoria, exaggerated feelings of well-being, and reduced self-control and then sedation and anesthesia (Figure 1).

The pathophysiological effects of long-term use of alcohol involve the same neurotransmitters but are complicated by tolerance and physical dependence as contributing factors to the problem of withdrawal of alcohol. Long-term alcohol intake (see Sidebar for indicators of alcohol dependence) results in a decrease in GABAA inhibitory function and an increase in NMDA excitatory function. Continued intake of alcohol causes adaptation of the central nervous system, reducing the initial, short-term effects. Abrupt cessation of intake of alcohol or withdrawal produces a rebound stimulatory effect, resulting in adrenergic hypersensitivity of the limbic system and brain stem, which can lead to irritability (manifested as aggressive behavior), tremors, and seizures.

Pathophysiology

The complex mechanisms of alcohol intoxication, tolerance, dependence, and withdrawal are not completely understood, but a clear relationship exists between alcohol and alterations in neurotransmission in the brain. Neurotransmitters are chemical messengers that transmit information from one neuron to another across synapses. Neurotransmitters in the brain either promote (excitatory) or slow down (inhibitory) impulses along the neurons.

One of the main neurotransmitters in the brain affected by alcohol is the inhibitory neurotransmitter γ-aminobutyrate A (GABAA). GABAA allows more chloride to enter the neuron, making the neuronal cell membranes less likely to depolarize, thereby inhibiting the cell. A second neurotransmitter of importance in alcohol abuse is the excitatory neurotransmitter N-methyl-D-aspartate (NMDA). NMDA regulates neuron excitability, increasing depolarization of the neuronal membrane by regulating the flow of calcium into the neuron. Initially, in short-term use (1 or 2 drinks occasionally), alcohol enhances the GABAA receptors and inhibits the NMDA receptors.

The result of short-term alcohol use therefore is depression of the behavioral inhibitory centers in the cerebral cortex and the reticular activating system, causing initial euphoria, exaggerated feelings of well-being, and reduced self-control and then sedation and anesthesia (Figure 1).

The pathophysiological effects of long-term use of alcohol involve the same neurotransmitters but are complicated by tolerance and physical dependence as contributing factors to the problem of withdrawal of alcohol. Long-term alcohol intake (see Sidebar for indicators of alcohol dependence) results in a decrease in GABAA inhibitory function and an increase in NMDA excitatory function. Continued intake of alcohol causes adaptation of the central nervous system, reducing the initial, short-term effects. Abrupt cessation of intake of alcohol or withdrawal produces a rebound stimulatory effect, resulting in adrenergic hypersensitivity of the limbic system and brain stem, which can lead to irritability (manifested as aggressive behavior), tremors, and seizures.

Pathophysiology

The complex mechanisms of alcohol intoxication, tolerance, dependence, and withdrawal are not completely understood, but a clear relationship exists between alcohol and alterations in neurotransmission in the brain. Neurotransmitters are chemical messengers that transmit information from one neuron to another across synapses. Neurotransmitters in the brain either promote (excitatory) or slow down (inhibitory) impulses along the neurons.
An additional problem that occurs with long-term use of alcohol is tolerance or a need to increase the amount of alcohol to obtain desired effects. Three types of tolerance develop.

The first type is metabolic tolerance or an increase in the rate of ethanol metabolism in the liver. As the ethanol is more rapidly metabolized, larger and still larger amounts of alcohol are needed to achieve the desired effects. The second type is cellular tolerance, which develops through the continued exposure of the cells in the brain to the neurochemical changes, the activities of GABAA, NMDA, and other neurotransmitters. Prolonged use of alcohol results in adaptation of the neurons to the use of alcohol, and larger doses of alcohol are needed to produce the same result. The third type is behavioral tolerance, learning to adapt behavior so the person can function under the influence of alcohol.¹

These 3 forms of tolerance can complicate the management of patients who have alcohol problems. For example, cellular tolerance may result in the need for increased dosages of medication to produce the desired results for a patient who has AWS.

Long-term alcohol dependency also leads to thiamine deficiency, a contributing factor to the pathophysiology of AWS. Thiamine deficiency occurs for 2 reasons: inadequate intake due to a poor nutritional state and interruption of the metabolism of thiamine by alcohol. Thiamine plays a key role in glucose metabolism. Thiamine pyrophosphate (the active form of thiamine) acts as a coenzyme for 2 enzymes in the Krebs or tricarboxylic acid cycle: 2-oxoglutarate dehydrogenase and pyruvate dehydrogenase. Most likely, a deficiency in thiamine pyrophosphate alters neuronal energy metabolism in the central nervous system and diminishes nerve transmission. The major organs affected by thiamine deficiency are those that depend on energy from the metabolism of carbohydrates: the peripheral nervous system, heart, and brain.

Peripheral neuropathy with myelin degeneration is the result of thiamine deficiency in the peripheral nerves. Cardiomyopathy and hypertension can occur because of effects of thiamine deficiency on the heart.¹ Wernicke encephalopathy and Korsakoff syndrome are the result of chronic thiamine deficiency in the brain. Wernicke encephalopathy is characterized by ophthalmoplegia (paralysis of the eye muscles), nystagmus (horizontal and vertical involuntary, rapid, rhythmic movements of the eyeballs), and ataxia (slow, uncertain, short-stepped gait). Signs and symptoms of Korsakoff syndrome include retrograde amnesia (inability to recall information), anterograde amnesia (inability to assimilate new information), decreased spontaneity, decreased initiative, and confabulation (filling in memory gaps with distorted facts).¹ Understanding the role of thiamine deficiency in long-term alcohol abuse is helpful in recognizing important clinical manifestations and in managing patients with AWS.

Clinical Features

Signs and symptoms of autonomic hyperreactivity and neuropsychiatric alterations characterize AWS. Autonomic hyperreactivity includes tremors, sweating, nausea, and vomiting. Neuropsychiatric alterations include agitation, anxiety, auditory disturbances, clouding of sensorium, and disturbances in visual or tactile senses. These signs and symptoms are somewhat nonspecific and therefore are easily confused with other problems common in critical care patients, such as electrolyte imbalances, pain, and infection.

The signs and symptoms of AWS usually occur within 24 hours after the last drink. They peak in 24 to 36 hours and end after 48 hours.⁵

Alcohol withdrawal delirium or delirium tremens can occur within 48 to 72 hours after the last drink. Delirium tremens is a serious and life-threatening complication of alcohol withdrawal and should be treated as a medical emergency. The peak time for occurrence of delirium is usually day 4 after cessation of alcohol use, and the delirium can persist for 2 to 3 days, or in severe cases, up to 2 weeks.¹ The pronounced autonomic hyperreactivity signs and symptoms of delirium include hypertension, tachycardia, tachypnea, and tremors. If untreated, these can lead to respiratory and cardiovascular collapse. Neuropsychiatric indications of delirium include hallucinations, confusion, disorientation, and impaired
attention. (See Table 1 for a summary comparison of the manifestations of AWS and delirium tremens.)

Laboratory values that may assist in recognition of AWS include mean corpuscular volume and serum levels of γ-glutamyl transferase, uric acid, and carbohydrate-deficient transferrin6 (Table 2). The values are abnormally increased with regular consumption of 180 to 240 mL (6-8 oz) of alcohol per day.5

### Assessment Tools

As a part of assessment at the time of admission to the critical care unit, all patients should be screened for alcohol abuse. The usual assessment includes an alcohol use history that includes the frequency and quantity of regular alcohol consumption, how many years the use has been occurring, and the most recent intake.

One tool that has been suggested as an assessment questionnaire for alcohol use is the CAGE tool7 (Table 3). Guidelines suggest that patients with a CAGE score greater than 2 or a score greater than 1 and at least 1 positive laboratory result (Table 2) should be considered alcohol dependent and at risk for AWS.7 The CAGE tool has been used in multiple studies and has documented reliability and validity in clinical settings. The advantage to using CAGE is that it is quick, easy to use, and easy to score.7

The Clinical Institute Withdrawal Assessment of Alcohol Scale, revised (CIWA-Ar; Figure 2) is a tool that can be used to objectively assess patients for the development of AWS. This scale has well-documented reliability and validity.8 It is a refined tool with a list of 10 signs and symptoms that is quick, easy to use, and useful in a variety of hospital settings, including psychiatric and general medical surgical units. The categories assessed in the CIWA-Ar include agitation, anxiety, auditory disturbances, orientation and clouding of sensorium, headache, nausea and vomiting, paroxysmal sweats, tactile disturbances, tremor, and visual disturbances.

The CIWA-Ar is used not only for diagnosis and monitoring but also as a basis for pharmacological management of patients with AWS. Scores of less than 8 to 10 on the CIWA-Ar indicate minimal to mild withdrawal.8 Scores of 8 to 15 indicate moderate withdrawal, and scores of 15 or more indicate severe withdrawal and impending delirium.8 By using the CIWA-Ar to assess patients, nurses

### Table 1 Clinical manifestations of alcohol withdrawal syndrome and delirium tremens

<table>
<thead>
<tr>
<th>Manifestation</th>
<th>Alcohol withdrawal syndrome</th>
<th>Delirium tremens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time of occurrence after last drink, hours</td>
<td>24</td>
<td>48-72</td>
</tr>
<tr>
<td>Autonomic hyperactivity</td>
<td>Tremors, Diaphoresis, Nausea, Vomiting, Headache, Agitation, Anxiety, Auditory disturbances, Clouding of sensorium, Tactile disturbances, Visual disturbances</td>
<td>Hypertension, Tachycardia, Tachypnea, Tremors, Hallucinations, Confusion, Delirium, Severe disorientation, Impaired attention</td>
</tr>
<tr>
<td>Neuropsychiatric alterations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 Laboratory values useful in recognizing alcohol withdrawal syndrome

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal value</th>
<th>Value in patients with chronic alcohol use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean corpuscular volume or mean cellular volume, µm³</td>
<td>82-98</td>
<td>Increased</td>
</tr>
<tr>
<td>Serum level of γ-glutamyl transferase, U/L</td>
<td>Men 4-25, Women 7-40</td>
<td>Increased</td>
</tr>
<tr>
<td>Serum level of uric acid, µmol/L (mg/dL)</td>
<td>0.24-0.51 (4.0-8.5)</td>
<td>Increased</td>
</tr>
<tr>
<td>Carbohydrate-deficient transferrin, g/L (mg/dL)</td>
<td>2.0-3.8 (200-300)</td>
<td>Increased</td>
</tr>
</tbody>
</table>

### Table 3 The CAGE questionnaire7

More than 2 positive responses to the questions suggest alcohol dependence.

1. Have you ever felt you ought to Cut down on drinking?
2. Have people Annoyed you by criticizing your drinking?
3. Have you ever felt Guilty about your drinking?
4. Have you ever had a drink first thing in the morning (Eye opener) to steady your nerves or to get rid of a hangover?
**Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)**

<table>
<thead>
<tr>
<th>Patient:</th>
<th>Date:</th>
<th>Time:</th>
<th>(24 hour clock, midnight = 00:00)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse or heart rate, taken for one minute:</td>
<td>Blood pressure:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Nausea and Vomiting
- **Ask** “Do you feel sick to your stomach? Have you vomited?” Observation.
- 0 no nausea and no vomiting
- 1 mild nausea with no vomiting
- 2 intermittent nausea with dry heaves
- 3 constant nausea, frequent dry heaves and vomiting

### Tactile Disturbances
- **Ask** “Have you any itching, pins and needles sensations, any burning, any numbness, or do you feel bugs crawling on or under your skin?” Observation.
- 0 none
- 1 very mild itching, pins and needles, burning or numbness
- 2 mild itching, pins and needles, burning or numbness
- 3 moderate itching, pins and needles, burning or numbness
- 4 moderately severe hallucinations
- 5 severe hallucinations
- 6 extremely severe hallucinations
- 7 continuous hallucinations

### Tremor
- Arms extended and fingers spread apart. Observation.
- 0 no tremor
- 1 not visible, but can be felt fingertip to fingertip
- 2 moderate, with patient’s arms extended
- 3 severe, even with arms not extended

### Auditory Disturbances
- **Ask** “Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things that you know aren’t there?” Observation.
- 0 not present
- 1 very mild harshness or ability to frighten
- 2 mild harshness or ability to frighten
- 3 moderate harshness or ability to frighten
- 4 moderately severe hallucinations
- 5 severe hallucinations
- 6 extremely severe hallucinations
- 7 continuous hallucinations

### Paroxysmal Sweats
- Observation.
- 0 no sweat visible
- 1 barely perceptible sweating, palms moist
- 2 beads of sweat obvious on forehead
- 3 drenching sweats

### Visual Disturbances
- **Ask** “Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing you? Are you seeing things that you know aren’t there?” Observation.
- 0 not present
- 1 very mild sensitivity
- 2 mild sensitivity
- 3 moderate sensitivity
- 4 moderately severe hallucinations
- 5 severe hallucinations
- 6 extremely severe hallucinations
- 7 continuous hallucinations

### Anxiety
- **Ask** “Do you feel nervous?” Observation.
- 0 no anxiety, at ease
- 1 mildly anxious
- 2 moderately anxious, or guarded, so anxiety is inferred
- 3 equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions

### Auditory Disturbances
- **Ask** “Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing you? Are you seeing things that you know aren’t there?” Observation.
- 0 not present
- 1 very mild severity
- 2 mild severity
- 3 moderate severity
- 4 moderately severe
- 5 severe
- 6 very severe
- 7 extremely severe

### Agitation
- Observation.
- 0 normal activity
- 1 somewhat more than normal activity
- 2 moderately fidgety and restless
- 3 paces back and forth during most of the interview, or constantly thrashes about.

### Orientation and Clouding of Sensorium
- **Ask** “What day is this? Where are you? Who am I?”
- 0 oriented and can to serial additions
- 1 cannot do serial additions or is certain about date
- 2 disoriented for date by no more than two calendar days
- 3 disoriented for date by more than two calendar days
- 4 disoriented for place and/or person

---

The CIWA-Ar is not copyrighted and may be reproduced freely.

---

**Figure 2** The Clinical Institute Withdrawal Assessment of Alcohol Scale, revised.

Available at: [www.erowid.org/chemicals/alcohol/alcohol_ARF_withdrawal_scale.shtml](http://www.erowid.org/chemicals/alcohol/alcohol_ARF_withdrawal_scale.shtml).

can quantify the potential for the development of AWS and therefore initiate treatment for patients who require therapy. The CIWA-Ar is not copyrighted and can be downloaded from the following Web site: www.erowid.org/chemicals/alcohol/alcohol_ARF_withdrawal_scale.shtml.

Management of Patients With AWS

The treatment plan for patients with AWS includes pharmacological management and supportive care.

Pharmacological Management

Most signs and symptoms of alcohol withdrawal are caused by the rapid removal of the depressant effects of alcohol in the central nervous system. Although many pharmacological agents have depressant effects on the central nervous system, the cornerstone of pharmacological management for AWS patients is benzodiazepines. These drugs are the only agents that have been proved in placebo-controlled trials to reduce the severity of the effects of alcohol withdrawal and prevent progression to the serious complications of AWS. Benzodiazepines work by potentiating the responses of the GABAA receptors, thereby enhancing neuronal inhibition, or putting on the brakes. At this time, no specific benzodiazepine is recommended for use. The choice of agent to be used should be guided by the agent’s duration of action, potential for abuse, and cost.

Benzodiazepines with a short-half life (eg, oxazepam, with a half-life of 4-14 hours, or lorazepam, with a half-life of 10-20 hours) result in rapid changes of drug levels in the blood and may have to be given at an interval of every 4 hours to avoid abrupt fluctuations of the drug levels, which may precipitate seizures. These short-duration agents may be particularly useful in patients with serious liver impairment or encephalopathy or when rapid control of signs and symptoms is needed. Agents with a longer duration of action (eg, diazepam, with a half-life of 20-90 hours, or chlordiazepoxide, with a half-life of 24-48 hours) may be used because they maintain the therapeutic levels more evenly and consistently and so provide more effective control of signs and symptoms.

Another consideration in selecting an agent for treatment is the potential for abuse of the drug. The results of some clinical trials indicate that certain agents are preferred by patients with addictive disorders. Agents with a rapid onset of action, such as diazepam or lorazepam, have a higher abuse potential than do agents with a slower onset, such as chlordiazepoxide or oxazepam.

In the current healthcare environment, cost of pharmacological management is also a consideration. Table 4 includes the approximate average wholesale costs of some of the benzodiazepines.

Because the goal of therapy is to alleviate the signs and symptoms of withdrawal, providing a fixed standardized dose of the selected benzodiazepine is not effective in treating alcohol withdrawal. Individualizing therapy according to the signs and symptoms (symptom-triggered therapy) of each patient results in administration of less medication and shorter treatment.

The CIWA-Ar can be used to provide guidance and to monitor effective treatment with benzodiazepines. Monitoring should be completed by using the CIWA-Ar every 4 hours, and if the score is greater than 8 to 10, the selected benzodiazepine should be administered (Table 4). One hour after administration of the drug, the CIWA-Ar should be used again to determine if further medication is needed. Monitoring should continue until the CIWA-Ar score is less than 8 to 10 for 24 hours.

Comorbid conditions and history of previous withdrawal seizures should also be considered when dosages of benzodiazepines are determined. The goal is to administer enough of the drug to alleviate the signs and symptoms and then to decrease the dose as the signs and symptoms abate.

Thiamine is another pharmacological agent recommended in the treatment of patients with AWS. The purpose of thiamine replacement is

| Table 4 Common benzodiazepines used to treat patients with alcohol withdrawal syndrome |
|-----------------------------------------------|-------------------|---------------------------|
| Drug                                          | Standard dose     | Recommended dose range for patients with alcohol withdrawal syndrome, mg |
|                                              | Amount, mg        | Cost, cents               |
| Chlordiazepoxide                              | 25                | 3                         | 50-100             |
| Diazepam                                      | 5                 | 7                         | 10-20              |
| Lorazepam                                     | 1                 | 11                        | 2-4                |
| Oxazepam                                      | 15                | 25                        | 10-30              |
to avoid the severe and irreversible complications (as discussed earlier) that can occur as a result of thiamine deficiency. A dose of 50 to 100 mg of thiamine is given parenterally or orally daily for 3 days or more.5

<table>
<thead>
<tr>
<th>System affected/ cancer risk</th>
<th>Effect</th>
<th>Mechanism</th>
<th>Nursing interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central nervous system</td>
<td>Impaired judgment and memory, Impaired balance and motor coordination, Sleep disturbances, Peripheral neuropathy, Alcohol-related psychiatric disorders, Dementia, Depression, Hallucinations, Wernicke encephalopathy, Korsakoff syndrome</td>
<td>Effects are due to the combination of the direct toxic effects of alcohol on neural tissue, thiamine deficiency, and nutritional deficits</td>
<td>Maintain patient’s safety, Provide quiet environment, Have patient avoid television and other activities that may contribute to hallucinations, Initiate interventions to prevent falls</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Beneficial effects, Possible reduction in risk for death due to cardiovascular conditions (1-2 drinks per day over long periods), Deleterious effects, Decreased myocardial contractility, Cardiomyopathy, Dysrhythmias, Mild to moderate hypertension</td>
<td>Beneficial effects occur because alcohol increases levels of high-density lipoprotein and decreases platelet aggregation, Deleterious effects are due to the direct toxic effects of alcohol on cardiac muscle and the vasopressor effects of ethanol</td>
<td>Monitoring patients for dysrhythmias, Provide rest to reduce fatigue, Monitor for hypertension</td>
</tr>
<tr>
<td>Hematopoietic</td>
<td>Increased size of red blood cells (mean corpuscular volume), Decreased production of white blood cells, Thrombocytopenia</td>
<td>Effects are due to the direct toxic effects of alcohol on bone marrow that cause suppression and malnutrition-related folate deficiency</td>
<td>Monitor blood values and bleeding, Do a complete nutritional assessment, Encourage patient to eat nutritiously, Maintain a safe environment and initiate interventions to avoid injury, Prevent infection</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Esophageal inflammation, Mallory-Weiss lesions, Esophageal varices, Acute pancreatitis, Alcohol-induced hepatitis, Cirrhosis</td>
<td>Effects occur because alcohol stimulates an increase in acid production and causes direct damage of the gastric mucosal barrier; cirrhosis occurs as a result of fatty buildup in the liver</td>
<td>Monitor patient for gastrointestinal bleeding, Monitor for alterations in liver function</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Alcoholic myopathy, Lower bone density, Increased risk of fractures</td>
<td>Effects on muscle tissue are due to the direct toxic effects of alcohol on muscle tissue. Skeletal effects are due to the direct toxic effects of alcohol on osteoblasts</td>
<td>Maintain a safe environment, Initiate interventions to prevent falls</td>
</tr>
<tr>
<td>Cancer risk</td>
<td>Increased risk for cancer of the Breast, Esophagus, Oral cavity, Overall risk of cancer is 10 times greater in persons who are alcoholic than in the general population</td>
<td>Alcohol is not a direct-acting carcinogen but one of its metabolites, acetaldehyde, may act as a tumor promoter. Chronic alcohol use also causes increased degradation of retinol by the liver and results in vitamin A deficiency, which is associated with an increased incidence of cancer</td>
<td>Explain effects of chronic alcohol use, Offer information on treatment options and sources of support</td>
</tr>
</tbody>
</table>

Supportive Care
The effects of alcohol on the body should be taken into consideration.
in supportive care (Table 5). Reducing environmental stimuli and providing uninterrupted periods of rest can help minimize the severity of signs and symptoms. Use of restraints should be avoided because they may worsen the neuropsychiatric alterations. Orientation should be provided as necessary with clocks and calendars. Use of television may contribute to a patient’s confusion and hallucinations, particularly if the program is unfamiliar to the patient. Because malnutrition is a concern with patients with AWS, providing adequate nutritional support is important. Monitoring fluid balance is important because fluid retention occurs as a result of the inhibition of vasopressin secretion, which occurs with increases in blood alcohol levels. In order to help reduce the stress of critical illness, which can exacerbate AWS, the concomitant medical disorder that brought the patient to the critical care unit should be aggressively treated.

Discharge planning should include encouragement to seek treatment for addictive disease. A nonjudgmental explanation of the effects of alcohol abuse and the possible complications can help patients make appropriate behavioral changes. Patients who abuse alcohol may be noncompliant with self-care management and are at risk for chronic AWS complications and increased likelihood of experiencing injury or trauma. Psychiatric support services and referrals are appropriate for follow-up.

Summary
Because alcohol abuse and alcohol dependency are widespread, many critical care patients may have AWS. AWS has marked consequences that affect the care of these patients, and critical care nurses must actively assess and intervene to prevent or at least minimize the complications of AWS. By increasing awareness, using reliable assessment tools, and knowing guidelines for the management of these patients, nurses can reduce the consequences of overlooking AWS and mismanaging patients who have the syndrome.

Acknowledgment
The author wishes to thank Kathy Kaminski, RN, for her encouragement and assistance in identifying the focus for this article.

References

1. What percentage of the population between the ages of 18 and 64 years meet the diagnostic criteria for alcohol dependency?
   a. 11%
   b. 18%
   c. 27%
   d. 34%

2. What are the mortality and morbidity rates of people who abuse alcohol compared to the general population?
   a. 1 to 3 times greater
   b. 2 to 4 times greater
   c. 2 to 5 times greater
   d. 1 to 2 times greater

3. What is the function of the neurotransmitter γ-aminobutyrate A?
   a. Allows more chloride to inhibit the cell
   b. Regulates calcium to inhibit the cell
   c. Allows less chloride to excite the cell
   d. Regulates calcium to excite the cell

4. What is the function of the neurotransmitter N-methyl-D-aspartate?
   a. Allows more chloride to inhibit the cell
   b. Regulates calcium to inhibit the cell
   c. Allows less chloride to excite the cell
   d. Regulates calcium to excite the cell

5. What is the term used to describe the effect resulting in hypersensitivity of the limbic system and brain stem when abrupt cessation of alcohol occurs?
   a. Rebound stimulatory
   b. Rebound depression
   c. Rebound hypersensitivity
   d. Rebound irritability

6. What are the 3 types of tolerances that develop with long-term alcohol use?
   a. Metabolic, cellular, and behavioral
   b. Metabolic, cognitive, and social
   c. Cognitive, cellular, and behavioral
   d. Behavioral, cognitive, and metabolic

7. Which vitamin deficiency plays a key role in long-term alcohol dependency?
   a. Vitamin A deficiency
   b. Vitamin B₁ deficiency
   c. Vitamin B₆ deficiency
   d. Vitamin C deficiency

8. In what metabolism does thiamine play a key role?
   a. Fat
   b. Protein
   c. Glucose
   d. Amino acid

9. What is the effect of thiamine deficiency on peripheral nerves?
   a. Myelin degeneration
   b. Myelin regeneration
   c. Excitation
   d. Depression

10. What are the 2 syndromes related to thiamine deficiency on the heart?
    a. Wernicke and Korsakoff
    b. Cardiomyopathy and hypertension
    c. Wernicke and cardiomyopathy
    d. Korsakoff and hypertension

11. What are the 2 syndromes related to thiamine deficiency on the brain?
    a. Wernicke and Korsakoff
    b. Cardiomyopathy and hypertension
    c. Wernicke and cardiomyopathy
    d. Korsakoff and hypertension

12. What is the cornerstone for pharmacological management of patients with alcohol withdrawal syndrome?
    a. Amphetamines
    b. Benzodiazepines
    c. Opiates
    d. Placebo

Test answers: Mark only one box for your answer to each question. You may photocopy this form.

1. ☐a  2. ☐b  3. ☐a  4. ☐a  5. ☐a  6. ☐a  7. ☐a  8. ☐a  9. ☐a  10. ☐a  11. ☐a  12. ☐a

Program evaluation
Objective 1 was met
Objective 2 was met
Objective 3 was met
Content was relevant to my nursing practice
My expectations were met
This method of CE is effective for this content
The level of difficulty of this test was:
 fácil  medium  difficult
To complete this program, it took me ______ hours/minutes.

Name ___________________________ Member # ________
Address ____________________________
City __________________________ State _______ ZIP ______
Country _______ Phone __________ E-mail address ______________________________
RN License #1 __________________________ State _______
RN License #2 __________________________ State _______
Payment by: ☐ Visa ☐ M/C ☐ AMEX ☐ Check
Card # ___________________________ Expiration Date ______
Signature ____________________________
Alcohol Withdrawal Syndrome Overlooked and Mismanaged?
Mary G. McKinley

Crit Care Nurse 2005;25 40-48
Copyright © 2005 by the American Association of Critical-Care Nurses
Published online http://ccn.aacnjournals.org/

Personal use only. For copyright permission information:
http://ccn.aacnjournals.org/cgi/external_ref?link_type=PERMISSIONDIRECT

Subscription Information
http://ccn.aacnjournals.org/subscriptions/

Information for authors
http://ccn.aacnjournals.org/misc/ifora.xhtml

Submit a manuscript
http://www.editorialmanager.com/ccn

Email alerts
http://ccn.aacnjournals.org/subscriptions/etoc.xhtml